Alan Kimura

Alan has extensive experience from a 32-year drug development career in both small biotech companies and large pharmaceutical organizations. He is a veteran in the development and execution of development programs for vaccines and rare disease therapeutics. Alan had a prominent role in the development of Prevnar® at Wyeth Vaccines and Bexsero® at Novartis Vaccines, and Elaprase® for the treatment of Hunter syndrome at Transkaryotic Therapies (now Shire/Takeda). He is currently Senior Vice President and Therapeutic Area Head for Rare Diseases at CureVac. Prior to CureVac, Alan served as Chief Medical Officer at Enzyvant and SutroVax (now Vaxcyte), and Vice President, Clinical Development at Translate Bio. Alan has held senior clinical development, research, and medical affairs roles at Shire, Novartis Vaccines, Altus Pharmaceuticals, Transkaryotic Therapies, BioChem Pharma, SmithKline Beecham Biologicals, and Wyeth Vaccines.

He has authored more than 30 publications and book chapters on vaccines and rare diseases. Alan received his M.D. from the University of Miami School of Medicine; an M.A. and Ph.D. from the University of California at Davis; and a B.A. from the University of California at Berkeley. He also conducted postdoctoral research in microbial pathogenesis at the University of Texas Health Science Center at Dallas (now UT Southwestern Medical Center).